North America Non Invasive Prenatal Testing Market Size & Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.

13-24 weeks was the largest segment with a revenue share of 50.84% in 2022. Horizon Databook has segmented the North America non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.

North America is one of the developed regions with high healthcare expenditure. It accounted for 43.38% share of the global market and is expected to maintain this dominant share during the forecast period. The rapid development of next-generation sequencing and reproductive genetics is a key factor driving the market growth. Furthermore, high R&D investments, high preterm birth rate, and increasing incidence of chromosomal abnormalities in the region are anticipated to boost the region’s non-invasive prenatal testing market. 

According to Trisomy 18 Foundation, Edwards syndrome affects around 1 out of every 2,500 pregnancies in the U.S. Presence of advanced healthcare facilities, well-established research framework, and development of whole genome sequencing in the region are anticipated to boost the growth of North America non-invasive prenatal testing market. As reported by Nordic Federation of Societies of Obstetrics and Gynecology, the U.S. lacks national consensus policies on the adoption of Noninvasive Prenatal Testing (NIPT). 

Thus, access to test programs is dependent on individual insurance companies and state Medicaid programs. Despite this, the testing programs have been widely implemented across the country, resulting in a larger revenue share of the region in the global market. Furthermore, domestic and global companies receiving U.S. patents for commercializing NIPT tests is driving the revenue in the region. Some of the companies/institutions are Verinata Health, Ravgen, Sequenom, Stanford University, Chinese University of Hong Kong, Isis Innovation Ltd., and the University of Louisville.